RedHill Biopharma Secures U.S. Government Funding Through BARDA to Advance Opaganib for Ebola Treatment
RedHill Biopharma secures U.S. government funding through BARDA to advance opaganib for Ebola treatment. Opaganib is a novel, potentially broad-acting, host-directed therapy, seeking to find an effective treatment for Ebola virus disease (EBOV).
Ebola is a fast-spreading and often deadly disease that needs better solutions. RedHill Biopharma and BARDA are betting on opaganib to potentially provide another easier-to-mobilize option to fight outbreaks.
